2024
Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice
Thomas J, Schindler E, Gottschalk C. Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice. Journal Of Clinical Investigation 2024, 134: e182556. PMID: 39087472, PMCID: PMC11290958, DOI: 10.1172/jci182556.Peer-Reviewed Original ResearchConceptsBlocking CGRP signalingCGRP receptor componentsMigraine-like painCervical lymph nodesGap junction proteinPrimary headache disordersLymphatic vessel dysfunctionAcute migrainePharmacological blockadeLymph nodesHeadache disordersNeurological symptomsJunction proteinsCGRPLymphatic vesselsMeningeal lymphatic vesselsInducible knockoutVessel dysfunctionMigraineReceptor componentsHeadachePainPathophysiologyDysfunctionMicePsilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial
Schindler E, Sewell R, Gottschalk C, Flynn L, Zhu Y, Pittman B, Cozzi N, D'Souza D. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. Journal Of The Neurological Sciences 2024, 460: 122993. PMID: 38581739, DOI: 10.1016/j.jns.2024.122993.Peer-Reviewed Original ResearchConceptsAttack frequencyCluster headacheCluster headache attack frequencyExtension phaseEffects of repeated treatmentReduction of attack frequencyPlacebo-controlled studyHeadache attack frequencyAdministration of psilocybinRandomized controlled trialsDouble-blindPsilocybin administrationPulse regimenAdverse eventsPulse regimensHeadache diaryTherapeutic efficacyDrug sessionsPulse administrationHeadacheStudy participantsWeeks
2023
Adapting psychedelic medicine for headache and chronic pain disorders
Schindler E, Hendricks P. Adapting psychedelic medicine for headache and chronic pain disorders. Expert Review Of Neurotherapeutics 2023, 23: 867-882. PMID: 37652000, DOI: 10.1080/14737175.2023.2246655.Peer-Reviewed Original ResearchConceptsChronic pain disordersPain disordersHeadache disordersChronic pain patientsRecent case reportsDifferent treatment paradigmsPsychedelic medicineSubstance use disordersMechanism of actionPain patientsChronic painCase reportClinical trialsTreatment paradigmTreatment outcomesTherapeutic effectLarge dosesUse disordersAdjunctive psychotherapyTherapeutic outcomesHeadacheBeneficial effectsSubjective effectsBranches of medicineDisordersThe Potential of Psychedelics for the Treatment of Episodic Migraine
Schindler E. The Potential of Psychedelics for the Treatment of Episodic Migraine. Current Pain And Headache Reports 2023, 27: 489-495. PMID: 37540398, DOI: 10.1007/s11916-023-01145-y.Peer-Reviewed Original ResearchConceptsEpisodic migrainePotential of psychedelicsWeekly migraine daysPsychedelic drugsMigraine daysPain intensityTransitional treatmentCluster headacheHeadache disordersPreventive effectClinical trialsSingle administrationTherapeutic effectAbortive effectMigrainePsychiatric conditionsReviewThis reviewTherapeutic agentsDrugsAdditional findingsMedicinal usePsychedelicsTreatmentPotential medicinal usePsilocybinCalcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder
Wang K, Fenton B, Deng Y, Anthony S, Dao V, Schindler E, Lipton R, Guirguis A, Skanderson M, Seng E, Sico J. Calcitonin Gene–Related Peptide Monoclonal Antibodies and Risk of SARS-CoV-2 Infection and Severe COVID-19 Outcomes Among Veterans With Migraine Disorder. JAMA Network Open 2023, 6: e2326371. PMID: 37523183, PMCID: PMC10391301, DOI: 10.1001/jamanetworkopen.2023.26371.Peer-Reviewed Original ResearchConceptsCalcitonin gene-related peptideSARS-CoV-2 infectionSevere COVID-19 outcomesCGRP mAbsMechanical ventilationSupplemental oxygenCOVID-19 outcomesSARS-CoV-2Cohort studyCGRP antagonistMAIN OUTCOMEMigraine disordersPositive SARS-CoV-2 test resultSARS-CoV-2 test resultsCOVID-19Protocol hazard ratiosRetrospective cohort studyMonoclonal antibody treatmentGene-related peptideLikelihood of hospitalizationCourse of diseasePeptide monoclonal antibodyElectronic health recordsNeuroimmune modulatorCumulative incidenceUnderstanding headache classification coding within the veterans health administration using ICD-9-CM and ICD-10-CM in fiscal years 2014–2017
Fodeh S, Fenton B, Wang R, Skanderson M, Altalib H, Kuruvilla D, Schindler E, Haskell S, Brandt C, Sico J. Understanding headache classification coding within the veterans health administration using ICD-9-CM and ICD-10-CM in fiscal years 2014–2017. PLOS ONE 2023, 18: e0279163. PMID: 36598881, PMCID: PMC9812322, DOI: 10.1371/journal.pone.0279163.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationHeadache diagnosisICD-10-CMICD-10-CM diagnosisICD-10-CM codingSpecialty care clinicsSpecific headache diagnosesICD-9-CM codingDifferent headache typesICD-9-CMRace/ethnicityHeadache comorbidityHeadache NOSPatient ageCare clinicsChronic conditionsHeadache typesProvider typeSociodemographic factorsHealth AdministrationDiagnosisTwo yearsHeadachePatientsMigraine
2022
The therapeutic potential of psychedelics
Schindler E, D'Souza D. The therapeutic potential of psychedelics. Science 2022, 378: 1051-1053. PMID: 36480624, DOI: 10.1126/science.abn5486.Peer-Reviewed Original ResearchExploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial
Schindler E, Sewell R, Gottschalk C, Luddy C, Flynn L, Zhu Y, Lindsey H, Pittman B, Cozzi N, D'Souza D. Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial. Headache The Journal Of Head And Face Pain 2022, 62: 1383-1394. PMID: 36416492, DOI: 10.1111/head.14420.Peer-Reviewed Original ResearchConceptsAttacks/weekPulse regimenCluster headachePsychotropic effectsAttack frequencyPlacebo-controlled studyPlacebo-controlled trialSerious adverse eventsEffects of psilocybinEffect sizeChronic participantsEfficacy outcomesAdverse eventsModerate effect sizeHeadache burdenHeadache disordersTherapeutic effectHeadache diaryPsilocybin administrationDrug sessionsExperimental drugsRegimenPsilocybin-containing mushroomsDefinitive studiesFinal analysisRecent advances in the diagnosis and management of cluster headache
Schindler EAD, Burish MJ. Recent advances in the diagnosis and management of cluster headache. The BMJ 2022, 376: e059577. PMID: 35296510, DOI: 10.1136/bmj-2020-059577.Peer-Reviewed Original ResearchConceptsCluster headacheHeadache disordersIpsilateral autonomic featuresChronic cluster headacheEpisodic cluster headachePrimary headache disordersFacial painDiagnostic delayTrigeminal neuralgiaSecondary causesTherapeutic featuresEffective treatmentUnilateral attacksHeadacheProper diagnosisNew treatmentsSuicidal ideationAutonomic featuresPainful human experiencesDisordersDiagnosisHigh rateRecent updatesTreatmentRecent advances
2021
Cluster Headache: Clinical Characteristics and Opportunities to Enhance Quality of Life
Grinberg AS, Best RD, Min KM, Schindler EAD, Koo BB, Sico JJ, Seng EK. Cluster Headache: Clinical Characteristics and Opportunities to Enhance Quality of Life. Current Pain And Headache Reports 2021, 25: 65. PMID: 34668084, DOI: 10.1007/s11916-021-00979-8.Peer-Reviewed Original ResearchConceptsQuality of lifeCluster headacheCommon psychiatric comorbiditiesCurrent clinical carePsychological treatmentPrimary headache disordersRecent FindingsPeopleClinical characteristicsSevere painPsychiatric comorbidityDisease burdenHeadache disordersClinical careDepressive symptomsGeneral populationHeadacheSuicidal ideationAutonomic featuresBehavioral interventionsCommitment TherapyPsychological factorsTreatmentBurdenComorbiditiesPainDemoralization predicts suicidality in patients with cluster headache
Koo BB, Bayoumi A, Albanna A, Abusuliman M, Burrone L, Sico JJ, Schindler EAD. Demoralization predicts suicidality in patients with cluster headache. The Journal Of Headache And Pain 2021, 22: 28. PMID: 33879041, PMCID: PMC8056539, DOI: 10.1186/s10194-021-01241-7.Peer-Reviewed Original ResearchConceptsLifetime suicidal ideationSuicidal ideationHigh suicide riskSuicide riskControl participantsDiagnostic criteriaBrief Lifetime Depression ScaleObservational case-control studyLifetime depression historyColumbia-Suicide Severity Rating ScaleCluster headache patientsCase-control studyEdition diagnostic criteriaActive suicidal ideationStepwise logistic regressionSeverity Rating ScaleCH sufferersLittle empiric dataOrbital painCH diagnosisCluster headacheHeadache patientsHeadache disordersDepression ScaleSuicidal Behaviors Questionnaire“You will eat shoe polish if you think it would help”—Familiar and lesser‐known themes identified from mixed‐methods analysis of a cluster headache survey
Schindler EAD, Cooper V, Quine DB, Fenton BT, Wright DA, Weil MJ, Sico JJ. “You will eat shoe polish if you think it would help”—Familiar and lesser‐known themes identified from mixed‐methods analysis of a cluster headache survey. Headache The Journal Of Head And Face Pain 2021, 61: 318-328. PMID: 33502769, DOI: 10.1111/head.14063.Peer-Reviewed Original ResearchConceptsCluster headache patientsCluster headacheHeadache patientsExercise/physical activityVitamins/supplementsSevere painInterventional investigationDisease management approachTreatment optionsSubgroup analysisPhysical activitySide effectsPatients' thoughtsMixed-methods analysisSecondary analysisFree-text responsesHeadachePatientsIllicit substancesDisease managementAdult participantsHeadache medicine
2020
Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
Schindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza D. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2020, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.Peer-Reviewed Original ResearchConceptsTherapeutic effectAdverse eventsSingle administrationPsychotropic effectsWeekly migraine daysSerious adverse eventsCross-over studyEffects of psilocybinOral placeboMigraine daysMigraine frequencyClinical effectsControlled StudyHeadache disordersMigraine headacheHeadache diaryDrug effectsDrug AdministrationNeuropsychiatric conditionsMigraineFinal analysisStudy proceduresReceptor ligandsWeeksAdministrationIn an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers
Schindler EAD, Schnakenberg Martin AM, Sewell RA, Ranganathan M, DeForest A, Pittman BP, Perrino A, D’Souza D. In an exploratory randomized, double-blind, placebo-controlled, cross-over study, psychoactive doses of intravenous delta-9-tetrahydrocannabinol fail to produce antinociceptive effects in healthy human volunteers. Psychopharmacology 2020, 237: 3097-3107. PMID: 32632491, DOI: 10.1007/s00213-020-05595-9.Peer-Reviewed Original ResearchConceptsCapsaicin-induced hyperalgesiaCross-over studyHealthy human subjectsIntravenous THCAcute painAntinociceptive effectDrug effectsDrug AdministrationHuman subjectsDose-related mannerPeak drug effectHealthy human volunteersSignificant antinociceptive propertiesRationaleAnimal studiesElectrical painPain conditionsPain managementChemical painPain ratingsAntinociceptive propertiesHealthy volunteersPsychoactive dosesAcute chemicalHuman studiesCognitive alterations
2018
Survey Analysis of the Use, Effectiveness, and Patient‐Reported Tolerability of Inhaled Oxygen Compared With Injectable Sumatriptan for the Acute Treatment of Cluster Headache
Schindler EAD, Wright DA, Weil MJ, Gottschalk CH, Pittman BP, Sico JJ. Survey Analysis of the Use, Effectiveness, and Patient‐Reported Tolerability of Inhaled Oxygen Compared With Injectable Sumatriptan for the Acute Treatment of Cluster Headache. Headache The Journal Of Head And Face Pain 2018, 58: 1568-1578. PMID: 30221765, DOI: 10.1111/head.13405.Peer-Reviewed Original ResearchConceptsInjectable sumatriptanCluster headacheAcute treatmentMedication responseOxygen deliverySide effectsPatient-reported side effectsSecondary analysisTherapeutic response rateCigarette smoking historyOptimization of therapyOptimal oxygen deliveryPositive predictorSmoking historyOxygen therapyCigarette smokingHeadache clinicTherapeutic optionsPatient populationPharmacologic interventionsTriptan medicationsComparable efficacyDaily attacksMale genderTherapeutic response
2016
Neuropsychiatric Presentation of Wilson Disease in an Adolescent Male
Schindler EA, Guo XM, Schrag M, Ghoshal S, Schilsky ML, Beslow LA. Neuropsychiatric Presentation of Wilson Disease in an Adolescent Male. Neuropediatrics 2016, 47: 346-347. PMID: 27490186, DOI: 10.1055/s-0036-1586225.Peer-Reviewed Original ResearchAdenosine TriphosphatasesAdolescentAggressionAntidepressive AgentsAntipsychotic AgentsAripiprazoleBrainCation Transport ProteinsCitalopramCopper-transporting ATPasesDepressionDiplopiaDysarthriaEsophageal and Gastric VaricesHepatolenticular DegenerationHumansHypertension, PortalImpulsive BehaviorLiver CirrhosisMagnetic Resonance ImagingMaleMutationSuicidal Ideation
2015
Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey
Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. Journal Of Psychoactive Drugs 2015, 47: 372-381. PMID: 26595349, DOI: 10.1080/02791072.2015.1107664.Peer-Reviewed Original ResearchConceptsCluster headacheIndoleamine hallucinogensConventional medicationsChronic cluster headachePain syndromePreventative medicationsAlternative medicationsLysergic acid diethylamideHeadache clinicConventional therapyCluster periodHeadacheMedicationsFinal analysisAcid diethylamideHallucinogensFurther investigationMost responsesSignificant numberAdditional evidenceParticipantsRemissionPatientsSyndromeClinic
2013
Clonidine Abuse in a Methadone-Maintained, Clonazepam-Abusing Patient
Schindler EA, Tirado-Morales DJ, Kushon D. Clonidine Abuse in a Methadone-Maintained, Clonazepam-Abusing Patient. Journal Of Addiction Medicine 2013, 7: 218-219. PMID: 23519051, DOI: 10.1097/adm.0b013e31828ab8d4.Peer-Reviewed Original Research